These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 6304836)

  • 21. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats.
    Bréard E; Belbis G; Hamers C; Moulin V; Lilin T; Moreau F; Millemann Y; Montange C; Sailleau C; Durand B; Desprat A; Viarouge C; Hoffmann B; de Smit H; Goutebroze S; Hudelet P; Zientara S
    Vaccine; 2011 Mar; 29(13):2495-502. PubMed ID: 21256877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
    Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
    Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune response of mice and sheep to bluetongue virus inactivated by gamma irradiation.
    Campbell CH; Barber TL; Knudsen RC; Swaney LM
    Prog Clin Biol Res; 1985; 178():639-47. PubMed ID: 2989913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of cross-protection of bluetongue virus serotype 4 with other serotypes in sheep.
    Zulu GB; Venter EH
    J S Afr Vet Assoc; 2014 Oct; 85(1):1041. PubMed ID: 25686101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors associated with the occurrence of undesired effects in sheep and goats after field vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4 and 16.
    Savini G; Cannas A; Casaccia C; Di Gialleonardo L; Leone A; Patta C; Nicolussi P
    Vet Microbiol; 2010 Nov; 146(1-2):44-50. PubMed ID: 20537822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a hemolysis-in-gel test for detection and quantitation of antibodies to bluetongue virus.
    Jochim MM; Jones SC
    Am J Vet Res; 1980 Apr; 41(4):595-9. PubMed ID: 6250425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of the minimum protective dose for bluetongue virus serotype 2 and 8 vaccines in sheep.
    Modumo J; Venter EH
    J S Afr Vet Assoc; 2012 Aug; 83(1):17. PubMed ID: 23327131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of viral antigens in bluetongue virus-infected ovine tissues, using the peroxidase-antiperoxidase technique.
    Cherrington JM; Ghalib HW; Sawyer MM; Osburn BI
    Am J Vet Res; 1985 Nov; 46(11):2356-9. PubMed ID: 3000230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of vaccination for bluetongue virus serotype 8 performed shortly before challenge and implications for animal trade.
    Spedicato M; Lorusso A; Salini R; Gennaro AD; Leone A; Teodori L; Casaccia C; Portanti O; Calistri P; Giovannini A; Savini G
    Prev Vet Med; 2017 Jan; 136():49-55. PubMed ID: 28010907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivated bluetongue virus vaccine in lambs: differential serological responses related to breed.
    Berry LJ; Osburn BI; Stott JL; Farver T; Heron B; Patton W
    Vet Res Commun; 1982 May; 5(3):289-93. PubMed ID: 6287706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine.
    Huismans H
    Onderstepoort J Vet Res; 1985 Sep; 52(3):149-51. PubMed ID: 3003649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental bluetongue virus infection of sheep; effect of previous vaccination: clinical and immunologic studies.
    Mahrt CR; Osburn BI
    Am J Vet Res; 1986 Jun; 47(6):1191-7. PubMed ID: 3014926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccines for bluetongue and other orbiviruses from a regulatory viewpoint.
    Strating A
    Prog Clin Biol Res; 1985; 178():627-9. PubMed ID: 2989911
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
    Roy P; Bishop DH; LeBlois H; Erasmus BJ
    Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nature and duration of protective immunity to bluetongue virus infection.
    Roy P
    Dev Biol (Basel); 2003; 114():169-83. PubMed ID: 14677687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A serological survey of bluetongue in Mozambique.
    Kanhai GK; da Silva R
    Bull Anim Health Prod Afr; 1981 Sep; 29(3):289-91. PubMed ID: 6286018
    [No Abstract]   [Full Text] [Related]  

  • 39. Bluetongue vaccine: cells and/or antibodies.
    Jeggo MH; Wardley RC
    Vaccine; 1985 Mar; 3(1):57-8. PubMed ID: 2988227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
    Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.